CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, today announced the signing of a Memorandum of Understanding (MoU) with Alfresa Holdings Corporation, one of Japan’s leading healthcare and pharmaceutical distribution groups, to establish a strategic collaboration for the development and future distribution of its lead product candidate ProtheraCytes® in Japan.

The agreement follows the recent publication of the EXCELLENT clinical trial results, supporting the therapeutic potential of ProtheraCytes®, an autologous CD34+ stem-cell product expanded through CellProthera’s unique manufacturing process, designed to regenerate cardiac tissue and improve cardiac function following acute myocardial infarction.

Under the terms of the MoU, the two companies intend to negotiate a definitive collaboration and licensing agreement covering the execution and financing of a Phase 3 clinical trial in Japan as well as the future distribution of ProtheraCytes® in the Japanese market.
The collaboration combines CellProthera’s expertise in regenerative cardiology and advanced cell therapy manufacturing with the Alfresa Group’s extensive healthcare infrastructure and nationwide pharmaceutical distribution capabilities.

“Japan is a strategic market for regenerative medicine and an important next step in the global development of ProtheraCytes®,” said Jérôme Koch, Chairman of the Board of CellProthera. “We are very pleased to enter this collaboration with Alfresa Holdings, a recognized leader in the Japanese healthcare ecosystem. Together, we aim to advance Phase 3 development and prepare the future commercialization of ProtheraCytes® for patients suffering from severe myocardial infarction.”

“We are delighted to initiate this collaboration with CellProthera,” said Yusuke Fukujin, Representative Director & Executive Vice President of Alfresa Holdings Corporation. “Regenerative medicine represents a major opportunity to address significant unmet medical needs in Japan. We believe CellProthera’s innovative CD34+ cell therapy has strong potential, and we look forward to working together to support its clinical development and future availability for Japanese patients.”

About CellProthera

CellProthera is a regenerative cell therapy developer specializing in cardiovascular diseases with a leading program in myocardial infarction. The company has developed a unique GMP-compliant cell production process as well as proprietary automation technologies for the production of expanded, purified CD34+ stem cells. Its lead therapy, ProtheraCytes®, is an autologous cell therapy, designed to promote vascular repair and cardiac regeneration, preventing the progression to heart failure after severe myocardial infarction. CellProthera is headquartered in France.

About Alfresa Holdings Corporation

The Alfresa Group is a leader in the Japanese healthcare industry and is dedicated to making its corporate philosophy, “we create and deliver a fresh life for all,” come true through a wide range of business lines, including ethical pharmaceuticals wholesaling, OTC pharmaceuticals wholesaling, pharmaceutical manufacturing, operating dispensing pharmacies, regenerative medicine-related business, and CRO business. Alfresa Holdings Corporation (TSE:2784) reported consolidated revenue of ¥3.1 trillion for the fiscal year ended March 31, 2026. For more information, please see: https://www.alfresa.com/eng/

 

Source: cellprothera.com

Report Abuse